Clovis (CLVS) options active on FDA accepts rucaparib NDA for priority review

August 23, 2016 3:27 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Clovis Oncology (NASDAQ: CLVS) September 25 calls and puts are active on total call volume of 13K contracts (8K puts) after FDA accepts rucaparib NDA for priority review. September call option implied volatility is at 99, October is at 101, January is at 98; compared to its 52-week range of 60 to 219.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities


Add Your Comment